TAVO-303

TAVO-303 is an investigational oncology agent initially developed by Tavotek Biotherapeutics as part of the Tavo-301/303 program for the treatment of cancer, but detailed public information on its molecular modality, specific target, or mechanism of action has not been disclosed. Available pipeline records list it under the therapeutic area of neoplasms and indicate that its global development status has been discontinued, suggesting that early-stage research or clinical development did not progress to later phases. Because Tavotek and its partners have not released technical data on the structure, class, or pharmacology of TAVO-303, its precise mechanism of action, route of administration, and intended tumor types remain unclear from publicly accessible sources.